Insight

Hagen Kennecke: Possible breakthrough in cancer cachexia with Ponsegromab

Photo of Hagen Kennecke taken from ohsu.edu

Sep 18, 2024, 12:58

Hagen Kennecke: Possible breakthrough in cancer cachexia with Ponsegromab

Hagen Kennecke, Section chief and Chief Health Officer of the OHSU Knight-Legacy Health Cancer Collaborative, shared on X:

“Possible breakthrough in cancer cachexia with Ponsegromab, anti-GDF 15. Significant weight gain, especially in patients with colorectal cancer.”

Ponsegromab for the Treatment of Cancer Cachexia | NEJM

Authors: John D. Groarke, Jeffrey Crawford, Susie M. Collins, Shannon Lubaczewski, Eric J. Roeland, Tateaki Naito, Andrew E. Hendifar, Marie Fallon, Koichi Takayama, Timothy Asmis, Richard F. Dunne, M.D., Isik Karahanoglu, Carrie A. Northcott, Magdalena A. Harrington, Michelle Rossulek, Ruolun Qiu, Aditi R. Saxena

Hagen Kennecke

Source: Hagen Kennecke/X

Aditi R. Saxena Andrew E. Hendifar cancer cancer cachexia Carrie A. Northcott Eric J. Roeland Hagen Kennecke Isik Karahanoglu Jeffrey Crawford John D. Groarke Koichi Takayama M.D. Magdalena A. Harrington Marie Fallon Michelle Rossulek ocnology OncoDaily Ponsegromab Richard F. Dunne Ruolun Qiu Shannon Lubaczewski Susie M. Collins Tateaki Naito Timothy Asmis

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 9

Shannon Miller and Ovarian Cancer: How She Went Against, How She Survived, and More

ASTRO Overview: Everything You Need to Know About the Leading Radiation Oncology Society

Ton Schumacher was bestowed the 2024 ESMO Award for Immuno-Oncology

A Turning Point in Cancer Treatment?

Special Coverage